Oncolytics Biotech Inc T.ONC

Madrigal Pharm up 260% from US$69 to $230 on 26vs10% result

[Noteable]

NASH results in the MAESTRO-NASH trial showed that patients on resmetirom 80 mg and 100 mg after 52 weeks of treatment had, respectively, NASH resolution of 26% and 30% compared to 10% for placebo.

For liver fibrosis, a ≥1-stage improvement in fibrosis with no worsening of NAFLD Activity Score (NAS) was seen in, respectively, 24% and 26% of resmetirom 80 mg and 100 mg patients and 14% of placebo patients.

https://www.google.com/search?q=madrigal+pharmaceuticals+stock&oq=madrga&aqs=chrome.3.69i57j46i10i131i199i433i465i512j0i10i131i433i512l3j0i10i512j46i10i512j0i3i10j46i10i512.8545j0j7&sourceid=chrome&ie=UTF-8

[Noteable]

Resulting in a current market cap US$ 4 Billion - on Madrgal Pharma's one drug in one indication. https://www.madrigalpharma.com/our-programs/resmetirom/

[Noteable]

A current stock price of US$242.50 is resulting in a current market cap of US$ 4.1 Billion - on Madrgal Pharma's one drug in one indication.

[Noteable]

Madrigal's current stock price of US$282.50 is resulting in a current market cap of US$ 4.8 Billion - on Madrgal Pharma's one drug in one indication.

[Noteable]

Madrigal Pharma closed today at a stock price of US$289.43 resulting in a current market cap of US$ 4.95 Billion - on Madrgal Pharma's one drug in one indication.

[TitanBrawler]

I can't. Believe the bullsh*t you spew notable. Freaking pathetic.

[Noteable]

The barking dogs are getting desperate.

[TitanBrawler]

Who gives a sh*t if  Madrigal Pharm up 260% from US$69 to $230 on 26vs10% result. Only someone as desperate as you would post something so stupid. Your true colors are showing. Thank you for clarifying.

[Noteable]

Madrigal Pharma stock price today at US$310.00 resulting in a current market cap of US$ 5.2 Billion - on Madrgal Pharma's one drug in one indication. One drug - one indication- valued at over US $ 5 Billion that falls at the lower band of Big Pharma's "sweet spot" of US$ 5 to $15 Billion for a M&A - the range that ONCY is looking at for an